Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 2/20 | 0.43 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23215107 | 1.00 | KMT2A (0.53) | KMT2AALKBH5SLC6A3PDPK1ALDH1A1 | |
| SCHEMBL11445431 | 0.89 | PTGS2 (0.53) | KMT2AALKBH5ALDH1A1FFAR1MAPT | |
| SCHEMBL31290437 | 0.82 | ALDH1A1 (0.51) | KMT2ASLC6A3ALDH1A1FFAR1GPR139 | |
| SCHEMBL11464880 | 0.81 | PPARG (0.44) | KMT2AALKBH5ALDH1A1CDC25BS100A4 | |
| SCHEMBL11445350 | 0.81 | GRIA4 (0.49) | KMT2AALDH1A1FFAR1MAPT | |
| SCHEMBL31290434 | 0.81 | CYSLTR2 (0.50) | ALDH1A1FFAR1CDC25BCYSLTR2CYSLTR1 | |
| SCHEMBL11446798 | 0.80 | FFAR1 (0.48) | KMT2AALDH1A1FFAR1MAPT | |
| SCHEMBL11446450 | 0.80 | CYP2A6 (0.43) | KMT2AALKBH5PDPK1CDC25BS100A4 | |
| SCHEMBL2577670 | 0.79 | SLC6A3 (0.65) | ALKBH5SLC6A3PDPK1ALDH1A1FFAR1 | |
| SCHEMBL6232946 | 0.79 | ALKBH5 (0.53) | ALKBH5SLC6A3PDPK1ALDH1A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20230089921-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| CN-114729044-A | Muscarinic acetylcholine M1Receptor antagonists | 帕珀莱恩医疗公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM3 | KMT2A 1589/4885ALKBH5 3838/4885SLC6A3 401/4885 |
| US-20230089921-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM3 | KMT2A 1093/4885ALKBH5 3515/4885SLC6A3 341/4885 |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM3 | KMT2A 1077/4885ALKBH5 3517/4885SLC6A3 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.